1976 Nobel Prize in Physiology or Medicine
Reason for Award
for their discoveries concerning new mechanisms for the origin and dissemination of infectious diseases
Laureates
United States of America
United States of America
Explanation
Germs and viruses that enter our bodies are tiny enemies that can make us sick. Dr. Blumberg studied blood samples and found a new enemy called the hepatitis B virus. Dr. Gajdusek showed that a strange brain disease spreading among forest people could actually be passed from one person to another. Together they asked, “How do diseases start and how do they spread?” Thanks to their work, doctors created vaccines and safer ways to give injections, saving many lives. Knowing the true face of a disease is a key to protecting everyone.
Related Keywords
hepatitis B virus
A DNA virus that spreads mainly through blood and body fluids, causing illnesses ranging from acute hepatitis to chronic hepatitis, cirrhosis, and liver cancer. Blumberg’s discovery of HBsAg opened the door to identifying the virus itself. Today, recombinant vaccines are widely used, successfully preventing mother-to-child transmission. Nevertheless, an estimated 200 million people remain chronically infected worldwide, sustaining a major public-health burden. Ongoing challenges include antiviral drug development and equitable vaccine delivery.
kuru
A fatal neurodegenerative disorder once prevalent among Papua New Guinea’s Fore people, characterized by ataxia and emotional lability. Gajdusek inoculated primates with brain tissue from patients and reproduced the disease after a long incubation, proving its infectious nature. The agent was later identified as a prion protein, illuminating other transmissible spongiform encephalopathies such as Creutzfeldt–Jakob disease. Ritualistic cannibalism served as the primary transmission route, and abolition of the practice led to a dramatic decline in cases. Kuru remains a textbook example that established the concept of prolonged-incubation infections.
serology
The collective science and techniques for detecting antibodies and antigens in blood to diagnose infections and immune status. Blumberg employed precipitin assays and radioimmunoassay to identify a novel viral antigen. His work improved transfusion safety and standardized screening tests, leading to modern ELISA and chemiluminescent assays. Tracking antibody titers over time also permits evaluation of vaccine efficacy and herd immunity. Even in the era of molecular diagnostics, serology remains central to infectious-disease epidemiology.
slow virus infection
A group of infections characterized by incubation periods spanning years to decades and a progressive, often fatal clinical course. Classic examples include kuru, subacute sclerosing panencephalitis, and animal scrapie. Gajdusek’s experiments demonstrated that such diseases could be caused by transmissible agents, introducing concepts like immune tolerance and neural tissue tropism. Prion diseases were later added, expanding the category beyond conventional viruses to “protein-only” pathogens. Slow infections continue to serve as key models for studying chronic inflammation and neurodegeneration.
horizontal transmission
The transfer of a pathogen between individuals other than parent to offspring. Blood transfusion, sexual contact, and reuse of medical instruments were recognized as key horizontal routes for hepatitis B virus. In the case of kuru, ritual cannibalism constituted an unusual horizontal pathway. Identifying transmission routes is essential for designing public-health policies and educational campaigns. Blocking horizontal spread, together with preventing vertical transmission, forms a twin strategy in infectious-disease control.
vaccine development
A technology that uses components or attenuated forms of pathogens to give the immune system a “practice drill,” preventing disease. Identification of HBsAg led to plasma-derived and later recombinant DNA vaccines, forming the backbone of WHO-led neonatal immunization programs. Large-scale, low-cost production has begun to narrow regional disparities in liver-cancer incidence. For kuru, no vaccine exists because the agent is a prion, but immunological interventions against abnormal protein pathogens are under investigation. Future vaccine platforms must ensure safety and efficacy while responding rapidly to emerging and re-emerging infections.